Scientific Advisory Board

Protagen is currently setting up an international scientific advisory board with key opinion leaders from the immuno-oncology and autoimmune disease fields. These expert panels will support our efforts in engaging with the medical and scientific community to develop products that are aimed at market needs.

Professor Vibeke Strand

Dr. Strand is a consultant in clinical research and regulatory affairs for pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years – in a subspecialty practice in San Francisco, as a clinical investigator and subsequently as Director of Clinical Research at three pharmaceutical and biotech companies, prior to establishing her consulting practice in 1991. She is a member of the clinical faculty at Stanford University, serving as Adjunct Clinical Professor, Division of Immunology and Rheumatology since September 2000, Clinical Associate Professor since March 1993 and previously at University of California San Francisco.

Her professional interests include development and validation of outcome measures, and clinical development and regulatory strategies leading to approval of new agents for treatment of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, gout and osteoarthritis. She has authored over 300 original publications and reviews, 50 chapters, co-edited several books and multiple proceedings.

She is a Master of the American College of Rheumatology (2015), Fellow of the American College of Physicians (1982), a founding member of the Executive Committee of the International Outcome Measures in Rheumatology (OMERACT) consensus effort (1992 – present), serves on the editorial board of multiple journals, and is a member of the Cosmos Club (1994).

Professor Matthias Schneider

Professor Schneider is Head of the Rheumatology Clinic, The Hiller Research Unit at Heinrich-Heine-University in Duesseldorf and Rhein-Ruhr, The Cooperation Multipurpose Arthritis Center. He is qualified within internal medicine, rheumatology, physical therapy and endocrinology and has been working in this field now for more than 30 years. In 1988, he was awarded the Venia Legendi for Internal Medicine. His major research interests include systemic connective tissue diseases, patient-reported outcomes and risk stratification of inflammatory rheumatic diseases.

From 2013–2014, he was President of the German Society of Rheumatology, and is still leading the development of guidelines for rheumatic diseases. He represented German rheumatology research in the EULAR recommendations for various topics in SLE. For more than 20 years he supported the German SLE patient group as a board member and has been a medical advisor of Lupus Europe since 2004.

Protagen is dedicated to the development of powerful diagnostic tools that aid successful therapeutic development and facilitate improved treatment strategies in the areas of autoimmune disease and immuno-oncology.

Protagen’s corporate leadership team combines over 40 years of commercial expertise and experience within the biotechnology industry, with a background spanning immunology, oncology, biomarker discovery and more.

Protagen has a number of established and committed investors, but is always looking at entering into new partnerships to help progress its research and commercialization efforts. If you are interested in investing in the company, please contact us.

Here you will find our quarterly newsletter, “Stratified News from Dortmund”. With our newsletter we intend to regularly update you on developments at Protagen in a fresh and colorful format and we hope that you like it. The newsletter is one way of interacting with you, our friends and collaborators, and we strive to improve our communication on an ongoing basis.